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Inhibitors of histone deacetylase (HDAC) are capable of arresting growth in cervical carcinoma cells in the G1 phase of
the cell cycle. Although HPV E6/E7 mRNA steady-state levels appeared to be constant after prolonged treatment, time-
course experiments revealed that viral transcription was transiently down-regulated between 7–10 h prior to cdk2 suppres-
sion. To test whether transitory suppression was a prerequisite for the biological outcome after HDAC inhibition, we took
advantage of two immortalized human keratinocyte cell lines in which E6/E7 oncogene expression was controlled by different
regulatory regions. After treatment with sodium butyrate (NaB) or trichostatin A (TSA), HPV16 upstream regulatory region
(URR)-directed transcription was down-regulated, showing kinetics similar to those in cervical carcinoma cells. In contrast,
-actin promoter controlled E6/E7 transcription was even temporarily increased and finally declined to levels initially
detected in the untreated controls. Both cell lines, however, were arrested in G1 and showed complete suppression of cdk2
activity that was preceded by a strong up-regulation of the cdk2 inhibitors p21CIP1 and p27KIP1. These results demonstrate that
growth of HPV16/18-positive cells can be arrested by HDAC inhibitors despite ongoing HPV transcription and thus
independently of any potential position effects uncoupling URR-directed gene expression by adjacent cellular promoters or
by downstream 3-polyadenylation sites after viral integration into the host genome during multistep carcinogenesis. © 2002erapy.Key Words: cervical cancer; cdk2 inhibition; p21; p27; th
INTRODUCTION
Chromatin-remodeling has received considerable at-
tention in the quest for developing therapeutic strategies
against certain forms of human cancer. Indeed, evidence
is accumulating which suggests that inhibitors of histone
deacetylases (HDAC), such as sodium butyrate (NaB),
trichostatin A (TSA), oxamflatin, and, as recently re-
ported, valproic acid, are very promising as agents that
can interfere with inappropriate cell proliferation or neo-
plastic transformation (for review, see Marks et al., 2001).
Mechanistically, inhibition of HDAC activity affects the
physiological equilibrium with antagonizing histone
acetylases (HAT), known to positively influence gene
expression by “opening” the heterochromatin for the tran-
scriptional machinery (for review, see Workman and
Kingston, 1998). Since neither enzyme shows sequence-
specific DNA-binding affinities on its own, the transcrip-
tional regulation of HATs and HDACs invokes the recruit-
ment of specific transcription factors to promoter regions
through protein–protein interaction (Ng and Bird, 2000).
For instance, particular coactivators such as p300/CBP
or p/CAF (the p300/CPB-associated factor) have intrinsic265HAT activity and can associate with CREB, c-jun, or p53
to promote transcriptional activation (Grant and Berger,
1999). Conversely, type 1 histone deacetylase (HDAC1) is
generally part of a repressor complex which physically
interacts with transcriptional repressors YY1, Mad/Max,
as well as the retinoblastoma protein, consistently lead-
ing to inhibition of gene expression (Johnson and Turner,
1999).
Cervical cancer is one of the most frequently found
malignant diseases in women worldwide. “High-risk” hu-
man papillomavirus types (e.g., HPV16 and HPV18),
which are causally involved in this disease (for review,
see zur Hausen, 2000), encode two oncogenes, E6 and
E7, capable of inducing immortalization of primary hu-
man keratinocytes (Barbosa and Schlegel, 1989; Hawley-
Nelson et al., 1989). Although E6 and E7 are not sufficient
to convert a cell in one step to malignancy (Du¨rst et al.,
1987), oncogene expression is apparently indispensable
for preserving the malignant phenotype. This was mainly
deduced from earlier observations where selective inhi-
bition of HPV transcription in cervical carcinoma cells via
“antisense” RNA or oligonucleotides resulted in a signif-
icant growth retardation under tissue culture conditions
and after heterotransplantation into nude mice (von
Knebel Doeberitz et al., 1988, 1992; Steele et al., 1993).Elsevier Science (USA)
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provide a reliable platform for developing further thera-
peutic concepts that aim to prevent HPV transcription
and in turn the growth of cervical cancer cells.
In an attempt to find alternative curative strategies, we
recently showed that the growth of cervical carcinoma
cells can also be arrested in the G1-to-S transition of the
cell cycle by entirely bypassing viral oncogene function.
This was achieved by HDAC inhibitors such as NaB and
TSA, which induce increased expression of the cyclin-
dependent kinase inhibitors (CKI) p21CIP1 and p27KIP1 and
complete suppression of the cyclin-dependent kinase
(cdk) 2 even in the presence of viral oncoproteins and
ongoing HPV transcription (Finzer et al., 2001).
Posttranscriptional circumvention of E6/E7 activity by
NaB/TSA is somehow reminiscent to previous cell hy-
bridization studies, where complementation groups be-
tween immortalized HPV16/18-positive keratinocytes
were established. Under these circumstances, cells en-
ter an irreversible growth arrest and start senescence
despite ongoing viral gene expression (Chen et al., 1993).
Although the molecular mechanism of oncogene impair-
ment still remains to be elucidated, hybrid formation and
subsequent cellular aging apparently unmask or activate
an inherent negative signaling cascade(s) through which
the function of E6/E7 becomes neutralized. In this con-
text, it is noteworthy that aging fibroblasts in fact accu-
mulate p21CIP1, which inactivates cyclin E-Cdk2 com-
plexes in senescent cells (Stein et al., 1999). In contrast,
as far as cervical carcinoma cells are concerned, not
only antisense RNA experiments unequivocally demon-
strate the necessity of continued E6/E7 expression in
maintaining cell proliferation (von Knebel Doeberitz et al.,
1988, 1992), but also reversible suppression of HPV 18
transcription and tumorigenicity in SW756 cervical carci-
noma cells (von Knebel Doeberitz et al., 1994).
Since we initially found indications for a transient
down-regulation of HPV18 mRNA after HDAC inhibition
(Finzer et al., 2001), we began examining viral transcrip-
tion after time-dependent application of HDAC inhibitors
both in HPV18-positive HeLa cells as well as in immor-
talized human keratinocytes. In the latter case, viral on-
cogenes of HPV16 were either controlled by their authen-
tic upstream regulatory region (URR) or by a cellular
promoter derived from the -actin gene (Mu¨nger et al.,
1989; Villa and Schlegel, 1991).
In the present study we show that HDAC inhibition
transiently suppresses transcription if HPV-URR con-
trolled, while viral oncogene expression was even in-
duced in cells when E6/E7 was directed by the -actin
promoter. Both keratinocyte cell lines, however, under-
went strong G1 arrest in the same temporal range,
whereby cdk2 activity was found to be completely abro-
gated due to increased binding of p21CIP1 and p27KIP1.
These data clearly demonstrate that transient suppres-
sion of viral gene expression is not a precondition to
exert NaB-/TSA-mediated growth inhibition on HPV-pos-
itive cells. This has important implications for future
therapeutic application of HDAC inhibitors, because the
function of the viral oncogenes can be circumvented at
the posttranslational level and therefore act indepen-
dently of positional effects resulting from different inte-
gration sites within the host genome.
RESULTS
Inhibitors of histone deacetylase transiently down-
regulate HPV transcription
Time-course experiments in HPV18-positive HeLa
cells in the presence of 6 mM NaB (Fig. 1A) showed that
viral transcription was selectively, but transiently, down-
regulated. This started at about 3 h, and the strongest
suppression could be discerned at 6 h, returning to
steady-state levels (after 16 h) as initially detected in the
untreated controls. For the cyclin-dependent kinase in-
FIG. 1. HPV regulation by sodium butyrate. (A) HeLa cells were
treated with 6 mM sodium butyrate (NaB) as indicated. (B) HeLa cells
were treated with NaB or with 5 g/ml actinomycin D (Act D) for
different periods of time. For Northern blot analysis, 5 g of total RNA
was separated in 1% agarose gels. The filters were hybridized with
probes specific for HPV 18, p21CIP1 (p21), GAPDH, or c-myc, respectively.
The positions of the 28S and 18S ribosomal RNA are indicated. Contr.:
untreated cells.
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hibitor p21CIP1, the corresponding transcript was already
elevated after 3 h and remained induced during the
whole incubation period. Subsequent hybridization of the
same filter with a housekeeping gene not affected by
HDAC inhibition (van Lint et al., 1996), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA, demon-
strated that transient suppression was in fact selectively
directed against the virus-specific transcription cassette
and did not represent the result of a nonspecific impair-
ment of total cell transcription. Similar kinetics were also
obtained with trichostatin A (data not shown), indicating
that transient HPV down-regulation is a feature generally
induced by HDAC inhibitors (see also Fig. 3A, below).
Nonetheless, although viral transcription reappeared,
cdk2 activity remained suppressed and ultimately the
growth of the cells was arrested (see Fig. 2A, below).
If transient down-regulation of HPV18 expression re-
sults from regulation at the level of initiation of transcrip-
tion, one can anticipate that the rate of mRNA decay after
NaB application should follow roughly similar kinetics as
with actinomycin D, known to nonspecifically block RNA
polymerase transcription by intercalating into DNA (Chen
et al., 1990). To clarify this question, cells were treated
separately either with 5 g/ml actinomycin D or with NaB
for different time intervals (1, 2, 3, 4, 5 h, respectively) and
the RNA was examined by Northern blot analysis. As
depicted in Fig. 1B, the relative abundance of the HPV-
specific transcripts began to decrease within roughly the
same time range (between 2 and 3 h) independently of
which inhibitor was applied. These data are in agree-
ment with preliminary nuclear run-on analyses, where
nascent HPV18 transcripts were also selectively dimin-
ished (data not shown). Since viral RNA, however, repro-
ducibly dropped more sharply 3 h after NaB (and TSA)
treatment when compared with actinomycin D, an addi-
tional posttranscriptional regulation cannot be excluded.
Expression of the c-myc gene, whose RNA is extremely
unstable in both normal and tumor cells (Dani et al.,
1985), was used as a further reference to assess the
biological activity of actinomycin D under our experimen-
tal conditions. Finally, it should be noted that, in contrast
to a recent report using oxamflatin as HDAC inhibitor
(Kim et al., 1999), de novo protein synthesis was not
required to abolish the biological effect of NaB or TSA on
HPV-positive cells, independently of whether simulta-
neous or subsequent incubation with cycloheximide was
carried out (data not shown, see also Discussion).
Time-course analysis of viral and cell-cycle regulatory
proteins after HDAC inhibition
Since it is supposed that the blockage of the growth
inhibitory function of CKIs through E7 binding represents
a key regulatory event during the development of cervi-
cal cancer (for review, see zur Hausen, 2000), we moni-
tored the time-course expression of p21CIP1 and p27KIP1
together with E7 by Western blot analysis. As demon-
strated in Fig. 2A, regulation of the mRNA (Fig. 1A)
closely correlates with the amount of the corresponding
protein, showing a significant reduction in the E7 onco-
protein 6 h after NaB application. However, there is
apparently no causal link between the time range of HPV
suppression and the extent of p21CIP1 and p27KIP1 protein
levels, because both CKIs reached their plateau when
the viral RNA was fully reexpressed (compare Figs. 1A
and 2A). Consistent with our previous findings, the
amount of cdk2 was not affected by NaB treatment (Fin-
zer et al., 2001).
To analyze the temporal range of cdk2 activity sup-
FIG. 2. Time course of cyclin kinase inhibitors and E7 regulation after
NaB treatment. (A) Western blot analysis: 75 g of total cellular protein
was loaded on a 12% SDS–PAGE gel. After electrotransfer, the filters
were incubated with antibodies directed against HPV18 E7, p21CIP1
(p21), p27KIP1 (p27), and cdk2. (B) cdk2 activity after NaB application.
Top: cdk2 complexes were immunoprecipitated and assayed for their
activity using histone H1 as substrate. Bottom: Western blot analysis of
the cdk2 complexes which were precipitated, separated in a 12%
SDS–PAGE gel, and immunoblotted with specific antibodies used in (A).
Loading was verified by incubation with cdk2 antibodies.
267EFFECT OF HDAC INHIBITION ON HPV-POSITIVE CELLS
pression, cyclin–cdk2 complexes were first immunopre-
cipitated with a cdk2-specific antibody and subsequently
functionally tested in an in vitro phosphorylation assay
using histone H1 as substrate (Fig. 2B, top). When com-
pared with untreated controls, cdk2 remained active up
to 9 h, but immediately declined between 12–16 h after
addition of NaB. To examine the association kinetics of
p21CIP1 and p27KIP1, the composition pattern of the cdk2
immunoprecipitates was examined by Western blot anal-
ysis. As depicted in Fig. 2B, cdk2 activity was sup-
pressed under conditions in which threshold amounts of
both CKIs became associated with the cdk2 complex
(between 12 and 16 h). Conversely, E7 bound to cyclin–
cdk2 complexes in control cells completely disappeared
between 12 and 16 h, despite ongoing viral RNA produc-
tion (Fig. 1A), and resynthesized intracellular E7 to quan-
tities comparable to those in untreated cells (Fig. 2B, see
also Fig. 2A for comparison). Incubation of the same filter
with a cdk2-specific antibody confirmed that approxi-
mately equal amounts were precipitated.
cdk2 inhibition and growth arrest in HPV16
immortalized keratinocytes expressing the viral
oncogenes under the control of a heterologous
promoter
Since it was claimed that continuous expression of the
viral oncogenes is indispensable to sustain proliferation
of cervical carcinoma cells both in vitro and in vivo (von
Knebel Doeberitz et al., 1988, 1991), the possibility still
exists that transitory suppression of HPV transcription is
a precondition for growth arrest via HDAC inhibition. To
analyze this issue in molecular terms, we took advantage
of two immortalized keratinocyte cell lines in which
HPV16 E6/E7 was under control of the HPV16 URR (des-
ignated as “1637”) or directed by a heterologous pro-
moter derived from the human -actin gene (referred to
as “1321”) (Mu¨nger et al., 1989; Villa and Schlegel, 1991).
Whereas p21CIP1 expression was augmented in both cell
lines 6 h following NaB addition, the time course of
transient HPV16 mRNA suppression in 1637 cells (Fig.
3A) was similar to that previously observed in HPV18-
positive HeLa cells (see also Fig. 1A). In contrast, a
strong up-regulation of HPV could be discerned in the
1321 cell line, where viral transcription was induced 3 h
after treatment and remained elevated during the entire
incubation period (Fig. 3B). Increased -actin promoter-
directed HPV16 expression was not the consequence of
a position effect after transfection, since the same was
obtained when endogeneous -actin expression was
examined (compare Figs. 3A and 3B). Note that after
prolonged incubation (16 h), HPV mRNA declined to the
basal levels initially detected in untreated cells (Fig. 4A).
Transcription was paralleled by protein reexpression,
showing equal amounts of HPV 16 E7 16 h after NaB
application when compared with corresponding controls
(Fig. 4B). Analogous results were obtained with TSA,
indicating that divergent HPV regulation was not a pe-
culiarity of NaB (data not shown). In any case, as already
depicted for HeLa cells (Fig. 2A), both cdk2 inhibitors
p21CIP1 and p27KIP1 were increased to the same extent,
independent of viral oncogene expression directed by
the HPV16-URR or by the -actin promoter, respectively
(Fig. 4A). Incubations of identical filters with a monoclo-
nal actin antibody again confirmed equal loading and
protein transfer.
Next, we determined the function of the cdk2 complex,
since it was conceivable that the elevated—instead of
FIG. 3. HPV16 transcription in immortalized keratinocytes after HDAC
inhibition. Keratinocytes immortalized with HPV16 E6/E7 (A) under
control of the homologues viral upstream regulatory region (“1637”) or
(B) under control of the -actin promoter (“1321”) were incubated with
NaB for various periods of time. Five micrograms of RNA was sepa-
rated in 1% agarose gels. The filters were hybridized with probes
specific for HPV16, p21CIP1 (p21), -actin, and GAPDH. The positions of
the 28S and 18S ribosomal RNA are indicated. Contr.: untreated cells.
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decreased—level of HPV16 expression in 1321 immor-
talized keratinocytes failed to block cdk2 activity despite
the accumulation of cyclin-dependent kinase inhibitors.
However, by monitoring cdk2 function after immunopre-
cipitation, it was found that both complexes revealed
high amounts of coprecipitated, and therefore physically
linked, p21CIP1 and p27KIP1, which accounts for the inability
of cdk2 to phosphorylate histone H1 as substrate when
assayed after 16 h (Fig. 5A). Abrogation of cdk2 activity
correlated with cell-cycle data obtained after flow cytom-
etry, where a significant accumulation of cells in G1 (from
54.2 to 65.3% for 1321 cells and from 65.3 to 81.2% for
1621 keratinocytes) was observed. Conversely, the pro-
portion of cells within S-phase was significantly de-
creased (31.5 to 18.6% for 1321 and from 24.9 to 4.7% for
1621, respectively) (Fig. 5B). These data clearly show that
transient down-regulation of HPV16/18 URR-controlled
transcription is not a precondition for the posttransla-
tional circumvention of virus-induced cell transformation
by HDAC inhibitors.
DISCUSSION
In the present article, we followed up our previous
study (Finzer et al., 2001) by analyzing the effect of HDAC
inhibitors on transcriptional regulation of high-risk HPVs
in more detail. Performing time-course experiments with
HPV18-positive cervical carcinoma cells (HeLa) in the
presence of NaB (or TSA), there was transient suppres-
sion of viral oncogene expression (Fig. 1A). Initial down-
regulation of HPV18 expression is most likely regulated
at the level of initiation of transcription, since the mRNA
decay was approximately in the same temporal range as
that with actinomycin D (Fig. 1B), a general inhibitor of
total cellular transcription (Chen et al., 1990). This as-
sumption was also substantiated by preliminary nuclear
run-on analyses, where the synthesis of nonprocessed
heterogeneous nuclear HPV18 RNA was also selectively
reduced (data not shown). However, since viral gene
expression declined consistently more rapidly than after
the addition of actinomycin D, an as yet unknown alter-
native mode of posttranscriptional mRNA labilization
cannot be ruled out.
A possible candidate that may account for the bipha-
sic transcriptional behavior is the transcription factor
FIG. 4. Expression of cell-cycle regulatory molecules after HDAC
inhibition. 1321 and 1637 cells were treated with 6 mM sodium butyrate
for 16 h. (A) Five micrograms of RNA was separated in 1% agarose gels.
The filters were hybridized with HPV 16, p21CIP1 (p21), and GAPDH-
specific probes. The positions of the 28S and 18S ribosomal RNA are
indicated. (B) Seventy-five micrograms of protein was separated in 12%
SDS–PAGE gels as described above (see Fig. 2).
FIG. 5. cdk2 suppression and cell-cycle arrest after NaB treatment. 1321 and 1637 cells were treated with 6 mM sodium butyrate for 16 h. (A) Top:
cdk2 complexes were immunoprecipitated and assayed for their activity using histone H1 as substrate. Bottom: Western blot analysis of the cdk2
complexes. Filters were incubated with specific antibodies against p21CIP1 (p21) and p27KIP1 (p27). Equal precipitation and loading was controlled by
incubation with a cdk2 antibody. (B) Flow-cytometric analysis: quantification of the proportion of cells in the cell-cycle phases G1, S, and G2/M
(standard deviations are the mean of three independent experiments). Control: untreated cells; NaB: sodium butyrate 6 mM.
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YY1. Due to its bifunctional nature, YY1 can either acti-
vate or repress not only a whole variety of cellular genes
(e.g., c-myc, c-fos, p53), but also HPV16/18 URR-directed
transcription (for review, see Shi et al., 1997). Interest-
ingly, as shown in a very recent study, acetylation of YY1
can activate its repressor function through interaction
with p300 and p/CAF, but there is also an intrinsic neg-
ative feedback loop which targets YY1 for deacetylation
by means of HDAC binding (Yao et al., 2001). For this
reason, transcriptional behavior of HPV probably de-
pends on the stoichiometric equilibrium between HDACs
and HATs associated with YY1 that may be counterbal-
anced during NaB/TSA treatment (Zhao et al., 1999). A
preexisting constellation of transcription factors could
also explain the independence of HDAC inhibition from
de novo protein synthesis. Further experiments must be
performed to elucidate this possible relationship in bet-
ter detail.
By monitoring the biological effect of HDAC inhibition
for up to 20 h after NaB addition by Western blot analysis,
a good concordance was found between the viral mRNA
levels and the amount of the corresponding E7 onco-
protein (Fig. 2A). Although continuous viral expression
elicits inappropriate S-phase entry via permanent cdk
activation (Zerfass-Thome et al., 1996; Funk et al., 1997;
Jones et al., 1997), cyclin kinase inhibitors p21CIP1 and
p27KIP1 were allowed to accumulate in a time-dependent
fashion, although the levels of E7 did not change (Fig.
2A). Moreover, dissection of the cdk2 complexes after
immunoprecipitation implies that blockage from G1-to-S-
phase transition was evidently mediated by functional
abrogation of cdk2 activity through enhanced p21CIP1 and
p27KIP1 binding ( failure of cdk2 to phosphorylate his-
tone H1) as well as concomitant preclusion of E7 binding
even if the amount of viral oncoprotein was not quanti-
tatively changed (Fig. 2B).
Since it has been described that E7 fails to rescue
cdk2 kinase activity in cells expressing high levels of
p21CIP1 (Hickman et al., 1997; Morozov et al., 1997), it was
tempting to speculate that the ability of HPV E7 to inac-
tivate p21CIP1 and p27KIP1 function might be concentration-
dependent. In other words, this particular temporal gap
of oncogene suppression (Fig. 2A) might allow the CKIs
to regain cell-cycle control. Indeed, a precedental case
for such a scenario has been reported recently for the
cervical carcinoma cell line HeLa. Growth inhibitory sig-
nals and ordered reactivation of tumor-suppressing path-
ways could be restored by introducing a truncated form
of the papillomavirus E2 protein, which represses tran-
scription by interacting with cognate-binding sites within
the HPV18 regulatory region (Goodwin and DiMaio,
2000). Ectopic E6/E7 expression under the control of a
heterologous promoter, however, completely failed to
rescue HeLa cells from E2-mediated growth arrest (Fran-
cis et al., 2000).
To assess the possible contribution of transient down-
regulation on the cell inhibitory effect of HDAC inhibitors
under our experimental conditions, HPV16 immortalized
human foreskin keratinocytes were used as a model in
which viral oncogene expression was controlled by dif-
ferent regulatory regions (Mu¨nger et al., 1989; Villa and
Schlegel, 1991). Figure 3A demonstrates that in 1637
cells transient HPV suppression by HDAC inhibitors was
again only detectable when expression was URR-con-
trolled. On the other hand, human -actin promoter-
driven expression was even increased (Fig. 3B) which
should—if the transcriptional interruption is indispens-
able—not permit CKIs to override E7 function. As dem-
onstrated in Figs. 4A and 4B, both CKIs became up-
regulated under conditions where viral transcription and
expression were sustained. The only noticeable differ-
ence to the situation previously found for HeLa cells was
the quantitative ratio of accumulated p21CIP1 and p27KIP1
16 h after NaB application.
Since there are no HPV-positive human keratinocytes
available with a biallelic disruption of p21CIP1, it is cur-
rently not clear which CKI definitively accounts for the
suppression of cdk2 activity. Considering, for instance,
the results obtained with p21(/) mouse embryo fibro-
blasts, butyrate-induced G1 arrest could also be
achieved in p21CIP1-deficient cells (Vaziri et al., 1998).
Moreover, p21CIP1 gradually increased in E7-expressing
keratinocytes upon differentiation while cdk2 was active
(for review, see Mu¨nger et al., 2001). However, compar-
ative studies examining the efficiency of various cyclin
kinase inhibitors on cell-cycle arrest and reduction of
tumorigenicity have demonstrated that p27KIP1 had the
most pronounced effect on HeLa cells when delivered by
adenoviral vectors (Schreiber et al., 1999; see also
Yamamoto et al., 1999). It is therefore reasonable to
assume that p27KIP1 is also a key player in our experi-
mental system. Nonetheless, cdk2 activity suppression
(Fig. 5A) and cell-cycle arrest (Fig. 5B) were accom-
plished in both immortalized keratinocyte lines (1321 and
1637), unequivocally demonstrating that HDAC inhibitors
can functionally neutralize the transforming potential of
E6/E7 of high-risk HPV type even in the presence of
continuing viral gene expression.
The posttranslational circumvention of viral oncogene
function has important implications for the potential ap-
plication of pharmacologically more stable NaB deri-
vates (Warrell et al., 1998) in future clinical trials, since
HDAC inhibitors can operate uncoupled from cis-regula-
tory mechanisms, which positively affect E6/E7 expres-
sion either by increasing the initiation rates of viral tran-
scription through adjacent cellular enhancers ( posi-
tion effects) (Ro¨sl et al., 1989; Jeon et al., 1995) or by
elevating viral mRNA half-life after fusion to downstream
cellular sequences (Jeon and Lambert, 1995). In fact,
preliminary flow cytometric analyses show that all cervi-
cal carcinoma cells tested so far underwent strong inhi-
bition in G1-to-S transition after treatment with butyrate
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or TSA (P. Finzer, M. Sto¨hr, U. Soto, N. Seibert, and F.
Ro¨sl, unpublished results) independently of the intracel-
lular amount of viral oncogenes.
MATERIALS AND METHODS
Cell lines
HPV-positive cervical carcinoma cell HeLa was main-
tained in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf serum (Gibco-BRL), 1%
penicillin, and streptomycin (Sigma). Human foreskin
keratinocytes transformed with HPV-16 E6/E7 either un-
der the control of a human -actin promoter (1321) or
under the control of the authentic upstream regulatory
region HPV (1637) were a kind gift of Dr. R. Schlegel
(Georgetown University, Washington, D.C.) (Mu¨nger et
al., 1989; Villa and Schlegel, 1991). Cells were grown in
three parts keratinocyte serum-free medium (K-SFM,
Gibco-BRL) and 1 part DMEM containing 10% fetal calf
serum (Gibco-BRL) and 0.75% gentamycin.
Reagents
The sodium salt of the n-butyric acid (Sigma) was
freshly resolved and diluted with cultivation medium.
Trichostatin A (Sigma) was prepared in dimethylsulfoxide
(DMSO) (Merck). Actinomycin D (Sigma) was dissolved
in water. 4,6-Diamidino-2-phenylindole-2HC1 (DAPI)
was supplied by Serva, Heidelberg, Germany and sulfor-
hodamine 101 (SR101) by Eastman Kodak, Rochester, NY.
DNA staining, flow cytometry, and cell-cycle analysis
Cells were harvested by trypsinization, washed twice
with phosphate-buffered saline (PBS), and fixed over-
night in 70% ethanol. After centrifugation, the cell pellet
was resuspended in a “DNA/protein staining solution”
containing DAPI (5  106 M) and SR101 (5  106 M) as
a protein counterstain following exactly the protocol pub-
lished by Stoehr et al. (1978). Cell-cycle analysis and
quantification of flow cytometric data was performed
according to Dean and Jett (1974).
RNA extraction and Northern blot analysis
Total cellular RNA was extracted according to the
guanidinium-thiocyanate procedure (Chomczynski and
Sacchi, 1987). Approximately 5 g RNA was separated
on 1% agarose gels in the presence of ethidium bromide
under non-denaturing conditions (Khandjian and Meric,
1986) and transferred to GeneScreen Plus membranes
(DuPont, NEN). The filters were hybridized under strin-
gent conditions with specific probes which were labeled
with 32P-dCTP by random priming (Feinberg and Vo-
gelstein, 1984).
Hybridization probes
pHF-A1 (Gunning et al., 1983), harboring an approx-
imately full-length insert of the fibroblast -actin gene,
was a generous gift from L. Kedes (Medical Center, Palo
Alto, CA). The plasmid c-myc containing the third exon of
the human c-myc gene was kindly made available by G.
Bornkamm (Institut fu¨r Klinische Molekularbiologie,
Mu¨nchen, Germany) (Polyak et al., 1987). The cDNAs for
p21CIP1 (El-Deiry et al., 1993) was kindly provided by B.
Vogelstein (John Hopkins Institute, Baltimore, MD) via P.
Jansen-Du¨rr (University of Innsbruck, Austria). The
GAPDH probe (Ercolani et al., 1988) was provided by A.
Alonso (Angewandte Tumorvirologie, DKFZ, Heidelberg).
The unit-length HPV 16/18 probes were a kind gift of M.
Du¨rst (Universita¨t Jena, Germany).
SDS–PAGE and Western blots
Cellular extracts were separated in 8–12% SDS–PAGE
gels and electrotransferred as described elsewhere
(Soto et al., 1999). The following antibodies were used:
cdk2 (D-12) (Santa Cruz Biotechnology, Inc.), p27KIP1
(K25020) and p21CIP1 (C24420) (Transduction Laborato-
ries), and HPV 16 E7 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). Equal protein transfer and loading was
routinely checked by incubating the filters with a mono-
clonal actin (ICN Biomedicals, OH).
Extract preparation, immunoprecipitation, and histone
kinase assays
For cell fractionation, cell monolayers were washed
twice with PBS and harvested by trypsinization. Cell-
extract preparation and cdk2 activity assays were done
exactly as described elsewhere (Blomberg and Hoff-
mann, 1999). In addition, cdk2 was immunoprecipitated
and analyzed by immunoblotting. Beads used for cdk2
kinase assay were washed three times with lysis buffer,
incubated with Laemmli sample buffer, and boiled for 5
min. Supernatants were analyzed by SDS–PAGE gels.
Immunoblotting was carried out with the following anti-
bodies: p21CIP1 (C24420) and p27KIP1 (K25020) (Transduc-
tion Laboratories) or HPV 18-E7 (N-19) (Santa Cruz, Inc.).
Cdk2-specific antibodies or preimmune serum were
kindly provided by I. Hoffmann (DKFZ, Heidelberg).
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